As a key mediator of normal physiological angiogenesis, vascular endothelial growth factor(VEGF) has been regarded as an emancipator to plastic surgeon, and yet a misfortune to oncology surgeon, due to its singular bi...As a key mediator of normal physiological angiogenesis, vascular endothelial growth factor(VEGF) has been regarded as an emancipator to plastic surgeon, and yet a misfortune to oncology surgeon, due to its singular biological effect. Therefore in some clinical cases, especially for some malignant tumor patients having endured radical surgery and being craving for a reconstructive surgery, VEGF plays a role full of paradoxes. To make a clinical balance, we should find a point to inhibit tumor cell from utilizing VEGF and make a permission to normal tissues to employ it.展开更多
抗体药物偶联物(antibody drug conjugates,ADCs)是一类新型的抗肿瘤药物,兼具有靶向药物的特异性和化疗药物的高度抗肿瘤活性,极具临床应用前景。近年来,乳腺癌的治疗正进入ADCs治疗时代,以恩美曲妥珠单抗、德曲妥珠单抗等为代表的ADCs...抗体药物偶联物(antibody drug conjugates,ADCs)是一类新型的抗肿瘤药物,兼具有靶向药物的特异性和化疗药物的高度抗肿瘤活性,极具临床应用前景。近年来,乳腺癌的治疗正进入ADCs治疗时代,以恩美曲妥珠单抗、德曲妥珠单抗等为代表的ADCs,为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)阳性乳腺癌患者的治疗带来了新的突破。此外,ADCs的出现,引入了“HER2低表达(HER2-low)”的概念,并为HER2-low的乳腺癌患者带来了生存获益。本综述重点探讨了ADCs在治疗HER2表达乳腺癌中的应用进展。展开更多
文摘As a key mediator of normal physiological angiogenesis, vascular endothelial growth factor(VEGF) has been regarded as an emancipator to plastic surgeon, and yet a misfortune to oncology surgeon, due to its singular biological effect. Therefore in some clinical cases, especially for some malignant tumor patients having endured radical surgery and being craving for a reconstructive surgery, VEGF plays a role full of paradoxes. To make a clinical balance, we should find a point to inhibit tumor cell from utilizing VEGF and make a permission to normal tissues to employ it.
